BridgeBio Pharma announces $500 million convertible notes offering to refinance debt, lowering interest costs and extending maturity.
Quiver AI Summary
BridgeBio Pharma, Inc. has announced the pricing of $500 million in convertible senior notes at a 1.75% interest rate, maturing in 2031, in a private offering aimed at qualified institutional buyers. The company plans to use the net proceeds, estimated at around $489.5 million, to repay its existing financing agreement, which will reduce interest expenses and provide more operational flexibility. Additionally, approximately $48.3 million will be allocated for repurchasing shares of common stock from certain purchasers of the notes at a price reflecting the current market rate. The notes will be convertible into cash or stock, and the conversion price represents a 45% premium over the recent stock price. Closing of the offering is expected on February 28, 2025, subject to customary conditions. The press release includes forward-looking statements, cautioning that actual results may differ due to various risks and uncertainties.
Potential Positives
- Refinancing the term debt facility significantly lowers interest expenses and eliminates near-term amortization payments, enhancing the company's financial flexibility.
- The offering of 1.75% convertible senior notes at a 45% conversion premium suggests strong market confidence in the company and provides necessary capital for growth.
- The termination of the prior financing agreement will allow for greater operational flexibility by removing various restrictive covenants.
- The planned share repurchase program could potentially increase the market price of the company's common stock, benefiting existing shareholders.
Potential Negatives
- The issuance of convertible senior notes indicates a reliance on debt financing, which may raise concerns about the company's overall financial health and ability to manage long-term obligations.
- The decision to repurchase shares using proceeds from debt raises questions about prioritization of capital allocation, especially in a competitive industry.
- The 45% conversion premium suggests a potential dilution of existing shareholders' equity, which could lead to dissatisfaction among investors.
FAQ
What is the main purpose of BridgeBio's recent offering?
The offering aims to refinance debt, lower interest expenses, and enhance operational flexibility.
What are the key terms of the convertible senior notes?
The notes have a 1.75% interest rate, due in 2031, with a 45% conversion premium.
How will BridgeBio use the proceeds from the offering?
Proceeds will repay existing borrowings, fund share repurchases, and support general corporate purposes.
What is the initial conversion price of the notes?
The initial conversion price is approximately $49.81 per share, reflecting a 45% premium over recent stock price.
When will the notes begin paying interest?
The notes will start paying interest on September 1, 2025, semi-annually thereafter.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- GENETIC DISORDER L.P. KKR sold 5,800,000 shares for an estimated $149,350,000
- GLOBAL INVESTORS LP VIKING sold 3,065,616 shares for an estimated $106,989,998
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 7 sales selling 658,932 shares for an estimated $23,542,500.
- BRIAN C STEPHENSON (Secretary, Treasurer & CFO) has made 0 purchases and 3 sales selling 76,304 shares for an estimated $2,710,871.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BBIO Hedge Fund Activity
We have seen 143 institutional investors add shares of $BBIO stock to their portfolio, and 138 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FARALLON CAPITAL MANAGEMENT LLC added 2,448,000 shares (+140.1%) to their portfolio in Q4 2024, for an estimated $67,173,120
- CITADEL ADVISORS LLC removed 1,686,753 shares (-57.3%) from their portfolio in Q4 2024, for an estimated $46,284,502
- WOODLINE PARTNERS LP added 1,261,772 shares (+132.9%) to their portfolio in Q4 2024, for an estimated $34,623,023
- PERCEPTIVE ADVISORS LLC removed 1,215,346 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $30,942,709
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,089,492 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $27,738,466
- PICTET ASSET MANAGEMENT HOLDING SA removed 995,585 shares (-35.5%) from their portfolio in Q4 2024, for an estimated $27,318,852
- ALYESKA INVESTMENT GROUP, L.P. added 940,415 shares (+inf%) to their portfolio in Q4 2024, for an estimated $25,804,987
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturity
Offering priced at 1.75% interest rate and 45% conversion premium
PALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1.75% convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $75 million aggregate principal amount of notes. The sale of the notes is expected to close on February 28, 2025, subject to customary closing conditions.
The Company estimates that the net proceeds from the sale of the notes will be approximately $489.5 million (or approximately $563.0 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and estimated offering expenses payable by the Company. The Company intends to use a portion of the net proceeds from the offering to repay all outstanding borrowings under and terminate its Financing Agreement, dated as of January 17, 2024, with the lenders party thereto and Blue Owl Corporation, as administrative agent, as amended (the “Financing Agreement”), and pay any fees related thereto. The termination of the Financing Agreement, which accounted for approximately $51.5 million of cash paid for interest in 2024 and contains various restrictive covenants, will provide the Company with reduced pro forma interest expense and greater operational flexibility.
The Company intends to use approximately $48.3 million of the remaining net proceeds from the offering to repurchase 1,405,411 shares of its common stock from certain purchasers of the notes in privately negotiated transactions effected through one of the initial purchasers or an affiliate thereof and entered into concurrently with the pricing of the notes (such transactions, the “share repurchases”). The agreed to purchase price per share of the Company’s common stock in the share repurchases is equal to the last reported sale price of the Company’s common stock of $34.35 per share on the Nasdaq Global Select Market on February 25, 2025. The share repurchases could increase (or reduce the size of any decrease in) the market price of the Company’s common stock, and could have resulted in a higher effective conversion price for the notes. The Company expects to use the remaining net proceeds from the offering for general corporate purposes.
The notes will bear interest at a rate of 1.75% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning September 1, 2025. The notes will mature on March 1, 2031, unless earlier converted, redeemed or repurchased. Prior to December 2, 2030, the notes will be convertible only upon satisfaction of certain conditions and during certain periods. Thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The notes will be convertible at the option of the holders, subject to certain conditions and during certain periods, into cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, with the form of consideration determined at the Company’s election.
The conversion rate will initially be 20.0773 shares of the Company’s common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $49.81 per share of the Company’s common stock). The initial conversion price of the notes represents a premium of approximately 45.0% over the last reported sale price of the Company’s common stock of $34.35 per share on February 25, 2025.
The Company may not redeem the notes prior to March 6, 2028. On or after March 6, 2028 and on or before the 41st scheduled trading day immediately before the maturity date of the notes, the Company may redeem for cash all or any portion of the notes, at its option at any time, and from time to time, if (i) the last reported sale price per share of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption and (ii) certain other conditions are satisfied. The redemption price will be equal to 100% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.
Holders of the notes will have the right to require the Company to repurchase all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of certain events.
When issued, the notes will be the Company’s senior unsecured obligations and will rank senior in right of payment to any of the Company’s unsecured indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment to any of the Company’s unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness and obligations to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of the Company’s subsidiaries.
The notes and the shares of common stock issuable upon conversion of the notes, if any, are not being registered under the Securities Act, or the securities laws of any other jurisdiction. The notes and the shares of common stock issuable upon conversion of the notes, if any, may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the Securities Act and any applicable state securities laws.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About BridgeBio
BridgeBio is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.
Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including statements relating to whether we will issue the notes, the anticipated use of the net proceeds from the offering and the expectations regarding the effect of the share repurchases, reflect our current views about our plans, intentions, expectations and strategies, which are based on the information currently available to us and on assumptions we have made.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024 and our other filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220
Source: BridgeBio Pharma, Inc.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
